The CCTG PR21 trial revealed a paradox: while Lutetium achieved a much higher PSA response rate than docetaxel chemotherapy, overall survival was better for patients who received docetaxel first. This counter-intuitive finding complicates treatment sequencing and challenges the assumption that higher initial response equals better long-term outcomes.

Recognizing that radioligand therapy is most effective early when tumors are "target-rich," new clinical trials accelerate dosing and intensity upfront. This strategy aims to deliver the most significant therapeutic blow before diminishing returns set in as the tumor responds and the target is lost.

The PSMA Addition study, adding lutetium in metastatic hormone-sensitive prostate cancer, showed an RPFS benefit. However, initial data suggested adverse quality of life scores. Upcoming results on pain and skeletal events are critical to determine if the toxicity profile undermines its clinical utility in this earlier disease setting.

The primary benefit of combining an androgen receptor inhibitor with lutetium-PSMA is a complementary, additive effect. The drugs target different cancer cell populations: the AR-inhibitor targets low-PSMA disease, while lutetium targets high-PSMA disease. This is more significant than any minor synergistic effect from PSMA upregulation.

Lutetium faces criticism for its fixed 6-cycle regimen, which may be suboptimal as the PSMA target diminishes with ADT. However, this critique is rarely applied to other drugs like PARP inhibitors, which are given until progression. This highlights a double standard and the tension between using a fixed regimen for regulatory approval versus finding the optimal dose in practice.

Blocking the androgen receptor with enzalutamide can increase PSMA expression. In patients on enzalutamide alone, this predicts a poor outcome. However, for patients receiving combination therapy, this increased expression creates a better target for lutetium-PSMA, effectively mitigating the negative prognosis and improving survival.

The CCTG PR21 trial revealed a paradox: patients treated with lutetium first had a PSA response rate double that of docetaxel chemotherapy. However, overall survival was better for the group that received docetaxel first. This highlights the complexity of sequencing and suggests initial response isn't always predictive of long-term outcomes.

Instead of administering all six planned doses of PSMA Lutetium upfront in the hormone-sensitive setting, a novel "sandwich" strategy is being considered. This involves giving a few doses, re-imaging, and reserving subsequent doses for later, potentially optimizing efficacy and managing long-term toxicity.

Expert analysis reveals a key weakness in many Lutetium-PSMA trials: the choice of the control arm. By comparing the novel therapy against a less-than-optimal standard of care, the trials may have been designed for an "easy win," dampening expert enthusiasm and raising questions about its true superiority over other potent hormonal therapies.